Skip Navigation


Mutagenesis Advance Access originally published online on September 29, 2006
Mutagenesis 2006 21(6):391-397; doi:10.1093/mutage/gel041
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/6/391    most recent
gel041v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by B.McKinzie, P.
Right arrow Articles by L.Parsons, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by B.McKinzie, P.
Right arrow Articles by L.Parsons, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Published by Oxford University Press 2006

ACB-PCR measurement of K-ras codon 12 mutant fractions in livers of Big Blue® rats treated with N-hydroxy-2-acetylaminofluorene

Page B.McKinzie1,*, Robert R.Delongchamp2, Tao Chen1 and Barbara L.Parsons1

1 Division of Genetic and Reproductive Toxicology HFT-120 3900 NCTR Road, Jefferson, AR 72079, USA 2 Division of Biometry and Risk Assessment, National Center for Toxicological Research 3900 NCTR Road, Jefferson, AR 72079, USA

K-ras codon 12 GGT->GAT and GGT->GTT mutations are the most frequently observed K-ras point mutations in human and rodent tumors and therefore are implicated in carcinogenesis for many tissues. Measurement of these mutations in rat models and human tissue could facilitate a more logical extrapolation of rodent tumorigenesis data to human disease. We have developed allele-specific competitive blocker PCR (ACB-PCR) assays for rat K-ras codon 12 GGT->GTT and GGT->GAT mutations that parallel the already published assays for human K-ras codon 12 mutations. Liver K-ras codon 12 mutant allele fractions were measured in vehicle-treated and N-hydroxy-2-acetylaminofluorene (N-OH-AAF)-treated Big Blue® rats. The average K-ras codon 12 GGT->GTT mutant fraction (MF) for four control rats was 50 x 10–6 (95% CI: 27 x 10–6, 95 x 10–6) and for four treated rats was 165 x 10–6 (95% CI: 87 x 10–6, 312 x 10–6), indicating a 3.3-fold increase with treatment (95% CI: 1.3–8.1). The average MF of K-ras codon 12 GGT->GAT for control rats was 1320 x 10–6 (95% CI: 498 x 10–6, 3500 x 10–6) and for treated rats was 8450 x 10–6 (95% CI: 3180 x 10–6, 22 400 x 10–6), indicating a 6.4-fold increase with treatment (95% CI: 1.6–25.4). These transgenic rats were part of a study that included analysis of liver lacI mutations. Although data from lacI determinations show that this compound induces mostly G->T mutations, using the ACB-PCR method both K-ras codon 12 GGT->GTT and GGT->GAT MFs were significantly increased in treated rats versus control rats. This data raises the possibility that N-OH-AAF may not only induce mutations by a genotoxic mechanism, but also by amplification of both de novo and pre-existing K-ras mutation.

*To whom correspondence should be addressed: Tel: +1 870 543-7399; Fax: +1 870 543-7393; Email: page.mckinzie{at}fda.hhs.gov


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.